Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIW815 (ADU-S100) in advanced solid tumors or lymphomas
NCT02675439Phase 1Terminated
- Sponsor
- Chinook Therapeutics
- Start
- Apr 2016
- Primary completion
- Dec 2019
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ADU-S100 in solid tumor and lymphoma (2 arms), sponsored by Chinook Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 6 months and Recommended dose at 6 months. Started Apr 2016; status: terminated.
02
Drugs
ADU-S100
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT02675439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675439.